Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

04 Oct 2023

The combination of hepatocyte-derived biomarkers and FibroTest or model for end-stage liver disease (MELD) scores can help identify patients with Child-Pugh class A alcohol-related cirrhosis who are prone to liver-related events at 2 years, reports a study.

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

04 Oct 2023

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

04 Oct 2023 bởi

Mental health symptoms of family members of patients hospitalized for acute respiratory distress syndrome (ARDS) were similar at 12 months regardless of whether it was caused by COVID-19 or not, a prospective cohort study suggests.

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

04 Oct 2023

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

04 Oct 2023 bởi

In a prospective study by the University of Hong Kong, long-term prophylaxis (LTP) with garadacimab or lanadelumab reduces attacks and improves quality of life (QoL) in Chinese patients with hereditary angioedema (HAE) who experienced frequent attacks. No adverse events (AEs) were reported.

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

04 Oct 2023

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

04 Oct 2023 bởi

Theo một nghiên cứu, việc sử dụng thuốc ức chế bơm proton (PPI) có thể làm tăng nguy cơ nhiễm trùng nghiêm trọng ở trẻ nhỏ.

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

04 Oct 2023

Ranitidine use not linked to increased cancer incidence

04 Oct 2023

Individuals with ranitidine exposure do not appear to be at increased risk of cancer compared with those who have exposure to other histamine-2 receptor antagonists (H2RAs), according to a study.

Ranitidine use not linked to increased cancer incidence

04 Oct 2023

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

04 Oct 2023 bởi

Theo nghiên cứu TRANSITION-T2D được trình bày tại ADA 2023, điều trị với semaglutide tiêm dưới da 1 lần/tuần và insulin degludec 1 lần/ngày giúp duy trì mức HbA1c ≤7.5% ở những bệnh nhân kiểm soát tốt đái tháo đường (ĐTĐ) type 2 đang sử dụng phác đồ tiêm insulin nhiều lần trong ngày (MDI).

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

04 Oct 2023

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

04 Oct 2023 bởi

First-line treatment with dabrafenib plus trametinib significantly increased overall response rate (ORR) in paediatric patients with low-grade glioma harbouring BRAF V600 mutations compared with standard chemotherapy, according to a recent study.

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

04 Oct 2023

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

03 Oct 2023 bởi

Among patients with hepatitis C virus (HCV) infection, the likelihood of achieving sustained virologic response (SVR) with direct-acting antivirals (DAAs) does not appear to be reduced among those who use alcohol or have alcohol use disorder (AUD), according to a study.

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

03 Oct 2023

LDL-C reduction prevents CVD in older adults

03 Oct 2023

Lowering bad cholesterol can help prevent major vascular events in older individuals aged ≥70 years similarly as those aged <70 years, suggests a recent study.

LDL-C reduction prevents CVD in older adults

03 Oct 2023

Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients

03 Oct 2023 bởi

Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.

Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients

03 Oct 2023

Tin tức & Cập nhật

Xem bài viết Đa khoa

Xem

Chuyên ngành:

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

Ranitidine use not linked to increased cancer incidence

Ranitidine use not linked to increased cancer incidence

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

LDL-C reduction prevents CVD in older adults

LDL-C reduction prevents CVD in older adults

Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients

Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients